{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:30:44Z","timestamp":1770017444942,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.antiviral.2011.03.175","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T05:04:34Z","timestamp":1301547874000},"page":"143-150","source":"Crossref","is-referenced-by-count":14,"title":["An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection"],"prefix":"10.1016","volume":"90","author":[{"given":"Yingyun","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.03.175_b0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody\u2013drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0010","first-page":"132","article-title":"Novel inhibitors of human CMV","volume":"9","author":"Andrei","year":"2008","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2011.03.175_b0015","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1073\/pnas.87.22.8889","article-title":"Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors","volume":"87","author":"Ashorn","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2011.03.175_b0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/j.1460-2075.1992.tb05089.x","article-title":"A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV","volume":"11","author":"Aullo","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2011.03.175_b0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF03401745","article-title":"Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein","volume":"4","author":"Bera","year":"1998","journal-title":"Mol. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000803","article-title":"Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs","volume":"6","author":"Berger","year":"2010","journal-title":"PloS Pathog."},{"key":"10.1016\/j.antiviral.2011.03.175_b0035","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.21108","article-title":"Multicentric Castleman\u2019s disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series","volume":"83","author":"Bestawros","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0040","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","article-title":"How I treat HIV-associated multicentric Castleman\u2019s disease","volume":"116","author":"Bower","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2011.03.175_b0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0050","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1086\/652869","article-title":"Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma","volume":"201","author":"Burbelo","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.03.175_b0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/rmv.583","article-title":"New approaches to the treatment of human herpesvirus 8-associated disease","volume":"18","author":"Casper","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/588820","article-title":"Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial","volume":"198","author":"Casper","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.03.175_b0065","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2003-05-1721","article-title":"Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2011.03.175_b0070","first-page":"1001","article-title":"Case records of the Massachusetts general hospital: case No. 40231","volume":"250","author":"Castleman","year":"1954","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0075","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA-sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0080","first-page":"54","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi\u2019s sarcoma, primary effusion lymphoma, and multicentric Castleman\u2019s disease","volume":"14","author":"Cesarman","year":"1997","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0085","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA-sequences in AIDS-associated Kaposis-sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2011.03.175_b0090","first-page":"215","article-title":"Kaposi\u2019s sarcoma (KS)-associated herpesvirus and its role in KS","volume":"5","author":"Chang","year":"1996","journal-title":"Infect. Agents Dis. \u2013 Reviews Issues and Commentary"},{"key":"10.1016\/j.antiviral.2011.03.175_b0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/335369a0","article-title":"Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein","volume":"335","author":"Chaudhary","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2011.03.175_b0100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/j.semnuclmed.2008.10.007","article-title":"Radioimmunotherapy of infectious diseases","volume":"39","author":"Dadachova","year":"2009","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0105","first-page":"56","article-title":"Kaposi\u2019s sarcoma in the era of HAART \u2013 an update on mechanisms, diagnostics and treatment","volume":"7","author":"Dittmer","year":"2005","journal-title":"Aids Rev."},{"key":"10.1016\/j.antiviral.2011.03.175_b0110","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1128\/jb.169.11.4967-4971.1987","article-title":"Exotoxin-A of Pseudomonas-aeruginosa \u2013 substitution of glutamic aid-553 with aspartic acid drastically reduces toxicity and enzymatic activity","volume":"169","author":"Douglas","year":"1987","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0115","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus-associated multicentric Castleman\u2019s disease: ANRS 117 CastlemaB trial","volume":"25","author":"Gerard","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1086\/315351","article-title":"Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy\/liv-scid-hu mice","volume":"181","author":"Goldstein","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.03.175_b0125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-128-8-199804150-00010","article-title":"The clinical behavior of localized and multicentric Castleman disease","volume":"128","author":"Herrada","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virol.2006.06.009","article-title":"Broad target cell selectivity of Kaposi\u2019s sarcoma-associated herpesvirus glycoprotein-mediated cell fusion and virion entry","volume":"354","author":"Kaleeba","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.03.175_b0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.transci.2007.04.011","article-title":"Castleman\u2019s disease and retroviral therapy","volume":"37","author":"Kenyon","year":"2007","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.antiviral.2011.03.175_b0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12185-010-0497-9","article-title":"Development of Kaposi\u2019s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient","volume":"91","author":"Law","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0150","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.1128\/JVI.78.24.13637-13652.2004","article-title":"Dissection of the Kaposi\u2019s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir","volume":"78","author":"Lu","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0255","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1086\/521625","article-title":"Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease","volume":"196","author":"Marcelin","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.03.175_b0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2169\/internalmedicine.46.6262","article-title":"Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman\u2019s disease","volume":"46","author":"Matsuyama","year":"2007","journal-title":"Intern. Med."},{"key":"10.1016\/j.antiviral.2011.03.175_b0160","first-page":"25","article-title":"Multicentric Castleman\u2019s disease in HIV infection: a systematic review of the literature","volume":"10","author":"Mylona","year":"2008","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2011.03.175_b0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/COH.0b013e328319bca9","article-title":"HIV-associated multicentric Castleman disease","volume":"4","author":"Oksenhendler","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2011.03.175_b0245","first-page":"503","author":"Pastan","year":"2003"},{"key":"10.1016\/j.antiviral.2011.03.175_b0250","first-page":"2479","author":"Pellett","year":"2007"},{"key":"10.1016\/j.antiviral.2011.03.175_b0180","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.4049\/jimmunol.142.9.3070","article-title":"Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates","volume":"142","author":"Pincus","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0185","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdn697","article-title":"The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman\u2019s disease","volume":"20","author":"Powles","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0190","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2007-08-106187","article-title":"Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease","volume":"110","author":"Powles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2011.03.175_b0195","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/leu.2008.54","article-title":"Successful treatment of multicentric Castleman\u2019s disease with combined immunochemotherapy in an AIDS patient with multiorgan failure","volume":"22","author":"Schmidt","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.antiviral.2011.03.175_b0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/path.1904","article-title":"The pleiotropic effects of Kaposi\u2019s sarcoma herpesvirus","volume":"208","author":"Schulz","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0205","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.addr.2008.04.011","article-title":"Use of antibodies and immunoconjugates for the therapy of more accessible cancers","volume":"60","author":"Sharkey","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2011.03.175_b0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0166-3542(95)00986-8","article-title":"Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections","volume":"32","author":"Smee","year":"1996","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2011.03.175_b0215","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA-sequence in multicentri Castleman\u2019s disease","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2011.03.175_b0220","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ajh.21137","article-title":"HIV-associated multicentric Castleman\u2019s disease","volume":"83","author":"Stebbing","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.antiviral.2011.03.175_b0225","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/592298","article-title":"Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease","volume":"47","author":"Sullivan","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.03.175_b0230","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.2847316","article-title":"HIV-infected cells are killed by rCD4-ricin A chain","volume":"242","author":"Till","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2011.03.175_b0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.virol.2004.03.049","article-title":"Use of the red fluorescent protein as a marker of Kaposi\u2019s sarcoma-associated herpesvirus lytic gene expression","volume":"325","author":"Vieira","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.03.175_b0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijmm.2008.08.003","article-title":"Pseudomonas exotoxin A: from virulence factor to anti-cancer agent","volume":"299","author":"Wolf","year":"2009","journal-title":"Int. J. Med. Microbiol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211002270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211002270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T23:42:22Z","timestamp":1686008542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211002270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0166354211002270"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.03.175","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}